Market ExpansionThe anticipated Phase 2 data for bivamelagon in hypothalamic obesity supports a favorable risk/reward balance, with potential for significant market expansion.
Regulatory SubmissionsThe data are a clear win for setmelanotide with RYTM planning regulatory submissions in both the U.S. and EU.
Safety ProfileBivamelagon's ability to spare MC1R offers a more favorable safety profile, potentially avoiding the hyperpigmentation side effects seen with IMCIVREE.